Aditya Juloori, MD

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025 02; 23(2):2-11.
PMID: 39938471

American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy.
American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. J Thorac Oncol. 2024 Dec; 19(12):1654-1667.
PMID: 39313150

Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society.
Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society. J Thorac Oncol. 2024 Dec; 19(12):1640-1653.
PMID: 39271016

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
PMID: 39242330

Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials.
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
PMID: 39106643

To Test and Preserve the Trachea.
To Test and Preserve the Trachea. Int J Radiat Oncol Biol Phys. 2024 Aug 01; 119(5):1333.
PMID: 39038905

Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
PMID: 38842838

Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer.
Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer. NPJ Precis Oncol. 2024 May 23; 8(1):114.
PMID: 38783041

Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2024 05; 22(4):249-274.
PMID: 38754467

Oncologic Safety of Close Margins in Patients With Low- to Intermediate-Grade Major Salivary Gland Carcinoma.
Oncologic Safety of Close Margins in Patients With Low- to Intermediate-Grade Major Salivary Gland Carcinoma. JAMA Otolaryngol Head Neck Surg. 2024 02 01; 150(2):107-116.
PMID: 38095911